Get started
Author

Isabel Echavarría

Observed names: I Echavarria, I. Echavarria, I. Echavarría, Isabel Echavarria
Observed institutions: Universidad Complutense de Madrid, Hospital Universitario Insular de Gran Canaria, Hospital Universitario La Paz, Hospital General Universitario Gregorio Marañón, Yale University, Hospital General Universitario Morales Meseguer, Complejo Hospitalario de Navarra, Centro de Investigación Biomédica en Red, Corporació Sanitària Parc Taulí, Hospital General Universitario de Elche, Hospital Universitario Central de Asturias, Instituto Murciano de Investigación Biosanitaria, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad de Murcia
ORCID: 0000-0002-1156-7681
Observed ORCID: 0000-0002-1156-7681
OpenAlex ID: A5039424220
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
2018 · Isabel Echavarria, Sara López-Tarruella, et al. · Clinical Cancer Research · 130
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
2017 · on behalf of the AGAMENON study group, Paula Jiménez Fonseca, et al. · British Journal of Cancer · 107
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
2023 · G. Villacampa, N.M. Tung, et al. · Annals of Oncology · 67
PDF
Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
2018 · Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, et al. · European Journal of Surgical Oncology · 59
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
2019 · A. C. Picornell, I. Echavarria, et al. · BMC Genomics · 57
PDF
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
2024 · M. Martín, S.R. Stecklein, et al. · Annals of Oncology · 53
PDF
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
2017 · on behalf of the AGAMENON study group, A Custodio, et al. · British Journal of Cancer · 51
El cáncer de mama
2015 · Miguel Martín, Ana Herrero, et al. · Arbor · 44
PDF
Assessment of a Genomic Assay in Patients With ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab
2023 · Coralia Bueno-Muiño, Isabel Echavarría, et al. · JAMA Oncology · 35
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
2025 · Guillermo Villacampa, Tomás Pascual, et al. · The Lancet Oncology · 33
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
2021 · Miguel Martin, Rocio Ramos-Medina, et al. · Scientific Reports · 33
PDF
Neratinib for the treatment of HER2-positive early stage breast cancer
2017 · Isabel Echavarria, Sara López-Tarruella, et al. · Expert Review of Anticancer Therapy · 30
How we Treat HR-Positive, HER2-Negative Early Breast Cancer
2022 · Sara Lopez-Tarruella, Isabel Echavarria, et al. · Future Oncology · 29
Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort
2024 · Rodrigo Sánchez-Bayona, Alfonso Lopez de Sa, et al. · Breast Cancer Research and Treatment · 26
SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
2023 · Jose Angel Garcia-Saenz, Isabel Blancas, et al. · Clinical & Translational Oncology · 26
PDF
Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
2016 · Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, et al. · Gastric Cancer · 24
PDF
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024 · Miguel Martín, Rachel Yoder, et al. · Clinical Cancer Research · 23
PDF
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
2016 · Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, et al. · Journal of the National Comprehensive Cancer Network · 22
PDF
Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
2017 · AGAMENON study group, A. Carmona-Bayonas, et al. · Gastric Cancer · 20
PDF
SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)
2022 · Isabel Echavarria, J. Rafael Carrión Galindo, et al. · Clinical & Translational Oncology · 19
Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study
2019 · Fernando Moreno, Javier Gayarre, et al. · JCO Precision Oncology · 14
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
2016 · Isabel Echavarria, Mónica Granja, et al. · Breast Cancer Research and Treatment · 12
Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit
2017 · Miriam Lobo, Sara López‐Tarruella, et al. · Journal of Genetic Counseling · 10
Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
2017 · Isabel Echavarria, Yolanda Jerez, et al. · Breast Care · 10
Ribociclib for the Treatment of Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
2017 · Sara López-Tarruella, Yolanda Jerez, et al. · Future Oncology · 7
Works count: 64
Citation count: 969
H-index: 19
I10-index: 24
Year
Topic
Type